Pancreatic disease cancer

Marxsen, J., Schmiegel, W., Roder, C., Harder, R., Juhl, H., Henne-Bruns, D., Kremer, B., and Kaithoff, H. (1994) Detection of the anti-p53 antibody response in malignant and benign pancreatic disease. Br. J. Cancer 70, 1031-1034. 

FIGURE 4.5 Representative spectrum examples of SELDI analysis of pancreatic juice samples bound to IMAC-3 cupper ProteinChip array. A peak of 16,570 Da (arrow) was present in the four pancreatic juice samples from patients with pancreatic adenocarcinoma (PC4, PCS, PC 18, PC24) but absent in the four patients with other pancreatic diseases (IPMN islet cell tumor (ICT) serous cystadenoma (SC)). (Reprinted from Rosty et al. [26], used with permission from the American Association of Cancer Research.)... 

Ichihara T, Nagura H, Nakao A, et al. Immunohistochemical localization of CA 19-9 and CEA in pancreatic carcinoma and associated diseases. Cancer. 1988 61 324-333. 

Alfthan H, Haglund C, Roberts P, Stenman UH (1992) Elevation of free beta subunit of human choriogonadotropin and core beta fragment of human choriogonadotropin in the serum and urine of patients with malignant pancreatic and biliary disease. Cancer Res 52 4628-4633... 

Pour, P.M., Runge, R.G., Birt, D., Gingell, R., Lawson, T., Nagel, D., Wall care, L., and Salmasi, S.S., 1981, Current knowledge of pancreatic carcinogenesis in the hamster and its relevance to human disease. Cancer, 47 1573-1587. 

After using C A19-9 as the only accepted diagnostic marker for pancreatic cancer for two decades [92], a bewildering number of potential biomarkers are currently under evaluation [93]. Apeak (3334.7 Da) found by SELDI-TOF-MS in 5/15 pancreatic adenocarcinoma cell lines was identified by Qq-TOF-MS/MS as the COOH-terminal fragment of DMBTl, a putative tumor suppression protein intracellularly generated by Umited prior proteolysis. Analyses of other cell lines suggested that the marker may be unique to pancreatic adenocarcinoma [94]. In another study, a differentially expressed peak (—16,570 Da) was detected in 10/15 samples from pancreatic adenocarcinoma in contrast to only 1/7 with other pancreatic diseases. The peak was identified as hepatocarcinoma-intestine-pancreas/pancreatitis-associated protein I (HIP-PAP I) by SELDI immunoassay [95]. 

Pancreatic carcinoma most frequently involves the head of the gland and usually presents with obstructive jaundice. About 10% of patients with pancreatic head cancer develop duodenal obstruction, usually quite late on in the course of their disease. Therefore most patients developing duodenal obstruction from pancreatic cancer will already have a biliary stent in... 

These drug are prescribed as replacement therapy for those with pancreatic enzyme insufficiency. Conditions or diseases that may cause a decrease in or absence of pancreatic digestive enzymes include cystic fibrosis, chronic pancreatitis, cancer of the pancreas,... 

AFP is a 70 kDa glycoprotein found in the circulatory system of the developing foetus. It is synthesized primarily by the yolk sac and (foetal) liver. AFP is present only in vanishing low quantities in the serum of adults (where it is replaced by serum albumin). Elevated adult serum levels of this marker are often associated with various cancers of the liver, as well as germ cell tumours. It is also sometimes expressed by gastric and pancreatic cancer cells. Although a useful tumour marker, increased serum AFP levels also often accompany cirrhosis and some other non-cancerous liver diseases. 

Gallbladder disease, hepatic adenoma, pancreatitis, thrombosis of abdominal artery or vein Endometrial, cervical, or vaginal cancer Deep vein thrombosis... 

And, finally, a remarkable study from the same group is on the feasibility of electrolytic ablation of tissue on a rat pancreas 85 it is worth mentioning that currently, there are no ablative techniques to treat pancreatic cancer in clinical use and this is an aggressive disease with less than 20% of patients suitable for a curative surgical resection. 

Cholecystokinin CCKa (CCKj) Human cDNA Anorexia, gastrointestinal disorders, pancreatitis, satiety, diabetes, obesity, nociception, schizophrenia, Parkinson s disease, addiction, cancer Pancreatic enzyme secretion, potentiation of opiate analgesia, gallbladder contraction, gut motility, growth promoting effects on some tumors, dopamine release... 

In more detailed analysis of the mortality experience of this cohort up to year end 1977, the results of other studies relative to an excess of lung cancer were not confirmed, but there were indications of a higher than expected mortality in pancreatic cancer, lymphohe-matopoietic cancers, genitourinary cancer, nonmalignant respiratory disease, and benign and unspecified neoplasms. ... 

While no in vivo activity has been reported in an Abl-dependent CML model, AZD0530 was active in a xenograft model using Src-transformed NIH 3T3 cells and in an orthotopic model of pancreatic cancer, two Src-dependent models. The results of a Phase I trial in normal volunteers have been disclosed and AZD0530 was tolerated when administered at doses of up to 250 mg [156,157]. While it appears that the initial efficacy trial for AZD0530 will be as an anti-invasive agent for the treatment of metastatic bone disease, this compound probably also has potential for use in CML. 

Within the multiple subsites of this tumor grouping, most work has been done in esophageal cancer. The large majority of these patients have been treated with paclitaxel in combination with radiation (Table 3). The experience with docetaxel is essentially limited to patients treated on phase I trials for thoracic malignancies that used radiation in combination with docetaxel (68,111). The situation is much the same for both pancreatic and gastric cancers as well. The rationale for looking at combination therapy that incorporates paclitaxel is much the same as in other disease sites, i.e., its activity in systemic disease (112), its potent preclinical radiosensitizing properties (38), and evidence from randomized trials that there is a benefit to combined modality therapy that includes at least radiation and chemotherapy (113-116). 

---